January Emerging Medical Technologies Report

Published January 2014 | 53 Pages | 60 Exhibits |


Order individually or subscribe and get a complete intel platform.


This report includes details on 60 emerging medical technology companies that have been identified by LSI's in-house research team in January 2014. Additionally, read LSI's "Innovator of the Month" Interview with:

- Uday Kumar, M.D., Cardiologist, Electrophysiologist, and Entrepreneur

All companies include technology, market(s), key executive, and contact information.

Coverage includes innovations in a broad spectrum of medical technology areas including:
- Aesthetics/Dermatology Companies
- Biomaterials Companies
- Biotechnology/Cell Therapy Companies
- Cardiovascular Companies
- Dental Companies
- Diagnostics Companies
- Drug Delivery Companies
- Endocrine Companies
- Gastroenterology Companies
- Gynecology/Women's Health Companies
- Imaging Companies
- Neurology Companies
- Oncology Companies
- Ophthalmology Companies
- Orthopedics Companies
- Pain Management Companies
- Patient Management/Monitoring Companies
- Pharmaceutical Companies
- Respiratory Companies
- Spine Companies
- Surgery Companies
- Urology Companies
- Vascular Companies
- Wound Management Companies

This report may be purchased separately or is automatically provided to subscribers of LSI's Emerging Medical Technologies® Database.


Table of Contents


•1-Disruptive percutaneous radio frequency (RF) device that can ablate tissues with a degree of unmatched precision and 2-A flexible endoscope for the destruction of localized lung tumors via RF ablation
•1-Formulations based on the isolation and purification of Eicosapentaenoic (EPA), 2-Soft gelatin encapsulation for the delivery of lipid-based drugs, and 3-Supplements for dental and women's health
•1-Inert protein nano-fiber sheets that provide temporary wound surface coverage and 2-Plant-protein based nano-fiber scaffolds with dermatological, neurological, cardiovascular, and vascular applications
•A disposable mobile device for painless self-injection of drugs for treating a wide variety of conditions, from cancer to hemophilia
•A molecular and cellular approach to treating diabetes, in which autologous liver cells are converted into functional insulin-producing cells
•A novel device therapy for hypertension, that incorporates an information technology component
•A sensor device intended to reduce complications due to improper management or dosing of anticoagulation drugs; the device will collect a patient's blood sample at home, then transmit data to the cloud - an algorithm would analyze the data and alert a doctor depending on the results
•A simple blood test that provides accurate early diagnosis of lung cancer
•Advanced prescription medications which have differential and therapeutically meaningful advantages to health care professionals and their patients
•Advanced wound care products
•Computer diagnostic system that enables easy use of genetic sequencing to screen for a variety of diseases
•Continuous medical-grade electrocardiogram, heart rate, heart rate variability, levels of physical activity, variations in body temperature monitoring and wireless data transmission for patients
•Drug for the treatment of chronic pruritus
•Drugs for the treatment of inflammation-related disorders and solid tumors
•Finger sleeve device that delivers mechanical and electrical stimulation to the finger to inhibit the sensation of sharp pain, with applications in diabetes (lancet pricks), arthritis, hand injuries, and wound healing
•First transfemoral venous access annuloplasty system for mitral regurgitation repair that can reproduce an effective surgical technique without open heart surgery
•Forward osmosis technology that allows intravenous solutions to be made using any kind of water (except sea water) at the point of care with no electricity, with an initial application in disaster relief
•Genetically-engineered stem cells to repair and replace damaged heart tissues resulting from heart attack/heart failure
•Highly scalable ultrasound systems that allow doctors to upgrade models easily without buyback situations
•Hormone receptor-targeting technology to develop cancer therapies
•Hormone therapies for the treatment and prevention of breast cancer and endocrine-related disorders, especially those affecting post-menopausal women and aging men
•Low-cost, portable ventilators
•Medical device potentially focused on the vascular space
•MicroRNA-based therapeutics and diagnostics to treat lung, ovarian, colorectal and prostate cancers
•Minimally invasive endodontic technology for complete 3D root canal cleaning and shaping using a single instrument
•Minimally invasive, needle-delivered neuromodulation devices for the gastrointestinal tract that replicate the therapeutic efficacy of bariatric surgery with minimal cost and risk
•Mobile health products and services to help healthcare professionals monitor and diagnose cardiovascular and other patients in a more efficient, accurate, and cost-effective manner
•Molecular diagnostics company focused on genetic screening of inherited diseases
•Molecular imaging technology to detect cancer in real-time during surgery, such as during breast cancer surgery
•Next-generation catheter-based devices for the treatment of cerebral aneurysms
•Next-generation diagnostic instrument based on the ultra-high speed, high-resolution Fourier-Domain Optical Coherence Tomography (FD-OCT) technology that will have significant benefit for patients with retina conditions
•Non-invasive blood glucose measurement device
•Non-invasive fetal electrocardiograph (fECG) monitor that is designed to report fetal heart rate (FHR) data equivalent to the gold standard fetal scalp electrode (FSE) in addition to novel ECG metrics intended to provide obstetricians a deeper understanding of fetal/maternal health and management
•Noninvasive, low-resistance medical device to help increase blood flow and reduce pain and swelling in the lower extremities, in patients with poor circulation
•Oral, small molecule drugs to address the underlying causes of chronic and severe, non-malignant blood-based diseases and genetic disorders for which there are currently no effective cures and only extremely limited therapeutic options
•Outpatient, endoscopically delivered, stent-like device that mimics gastric bypass surgery for the treatment of obesity and type 2 diabetes
•Pipeline of potent anti-infective agents that can be delivered directly to the lung by inhaled administration, for the treatment of life-threatening lower respiratory tract viral and fungal infections
•Pocket-sized spirometer to measure lung function in asthma patients, that seamlessly connects with mobile and web apps
•Portable stroke detection device for use in the emergency room to improve triage times and enable faster diagnosis and treatment
•Portable, non-invasive head trauma screening device for use in measuring intracranial pressure in pre-hospital settings, and detecting traumatic brain injury and brain hemorrhage
•Portable, non-invasive, non-mydriatic eye pre-screening device that can detect diabetic retinopathy, cataracts, glaucoma, cornea problems and refractive errors
•Portfolio of reprofiled, low-risk, and/or orphan products targeting ocular surface diseases, glaucoma/glaucoma surgery, and retinal diseases
•Programmable implantable drug pump that is differentiated from existing technology through its new and innovative features
•Proprietary class II orthopedic and spine products, including an interbody fusion device sprayed with titanium plasma
•Proprietary technology focused on rapid, robust isolation of clinically actionable genetic biomarkers from blood, urine and cerebrospinal fluid for diagnosis, monitoring and companion diagnostic applications
•Rapamycin-related drugs to slow the aging process and potentially ward off aging-related diseases such as Alzheimer's
•Second-generation intra-luminal intestinal liner that mimics the effects of bariatric surgery in causing remission of Type 2 Diabetes accompanied by weight loss and is endoscopically implanted via a 30-minute procedure, without the need for surgery
•Sensor technologies used in biometric impact measurement for sensing traumatic brain injury (TBI), such as in high-impact sports; data transmitted wirelessly to sports officials and to secure cloud database
•Single "soft" but permanent gelatin implant to provide significant, long-term intraocular pressure (IOP) control, which may reduce the risk of glaucoma disease progression and associated vision loss in mild, moderate, and refractory glaucoma patients
•Single-use organ preservation device to improve donor organ quality and extend donor organ preservation times
•Single-use, implantable arterio-venous shunt that provides a unique, non-surgical approach for patients who need vascular access
•Small molecule drugs for the treatment of inflammatory and autoimmune diseases and organ transplant rejection, based on the specific inhibition of calcium release-activated calcium (CRAC) channels
•Smartphone-based autorefraction vision test technology
•Stethoscope accessory connected to portable devices for mobile heart sound, three-lead electrocardiogram, and cloud-based diagnostic support
•Therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level
•Three-dimensional (3D) nanofiber scaffolds for use in regenerative medicine and 3D cell culture
•Transformative technology to improve vein performance and longevity in coronary artery bypass grafts (CABG)
•Unique set of compounds to protect hearing and silence tinnitus
•Vascular closure system that uses a proprietary medical adhesive to close the saphenous vein, thereby eliminating the need for surgery, ablation, anesthesia, or the use of harsh chemicals to treat venous reflux disease
•Venipuncture automation system

Accelerate your business

We’re here to help you make smarter decisions and form stronger partnerships through curated events, independent market intelligence products and services, and digital-forward media.